| 2024 | | Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study | 강석윤 |
| 2024 | | Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset | 최진혁 |
| 2024 | | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | 이현우 |
| 2024 | | A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial | 이현우 |
| 2024 | | CDK4/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents | MUHAMMAD, IMRAN, 김영화, 박태준, 최용원, 최재호 |
| 2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | 이현우 |
| 2024 | | Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study | 강석윤, 고영화, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2024 | | Cellular senescence is associated with the spatial evolution toward a higher metastatic phenotype in colorectal cancer | 김영화, 김장희, 박순상, 박태준, 이영경, 임수빈, 최용원 |
| 2024 | | Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial | 강석윤 |
| 2024 | | Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study | 이현우 |
| 2023 | | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | 정성현, 최윤석 |
| 2023 | | A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13) | 안미선 |
| 2023 | | Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404) | 정성현 |
| 2023 | | Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response | 권민석 |
| 2023 | | Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation | 정성현, 최윤석 |
| 2023 | | Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma | 고영화, 박범희, 이현우, 한재호, 함석진 |
| 2023 | | Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non–Small Cell Lung Cancer | 고영화, 변혜은, 이현우, 한재호, 함석진 |
| 2023 | | The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma | 노진, 박준성, 정성현, 최윤석, 한재호 |
| 2023 | | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial | 최진혁 |
| 2023 | | Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01) | 최진혁 |
